Roche draws emerging markets battle lines with launch of cut-price Herceptin and MabThera in India
This article was originally published in Scrip
Executive Summary
Roche has launched cut-price brands for Herceptin (trastuzumab) and MabThera (rituximab) locally in India but underscored the role of governments in sustaining healthcare plans in their countries.
You may also be interested in...
Russian Blitz, Glenmark Peek Await Indian Biosimilars Arena
Potential new entrants appear to be priming varied approaches to the competitive biosimilars market in India. While a full-fledged Russian challenge may be on the horizon as Biocad readies a basket of products for the Indian market, local firm Glenmark, which has been keen to stay focused on new biological entities (NBEs), now appears to be dipping its toe into the biosimilars segment.
Russian Blitz, Glenmark Peek Await Indian Biosimilars Arena
Potential new entrants appear to be priming varied approaches to the competitive biosimilars market in India. While a full-fledged Russian challenge may be on the horizon as Biocad readies a basket of products for the Indian market, local firm Glenmark, which has been keen to stay focused on new biological entities (NBEs), now appears to be dipping its toe into the biosimilars segment.
Litigation Aside Biosimilar Avastin Just Got Cheaper In India
Another biosimilar version of Roche's anticancer, Avastin (bevacizumab) has just arrived on the Indian market despite the shadow of ongoing litigation. The launch, cheered by some activists, takes prices of biosimilar bevacizumab lower, amid allegations that Roche has been pursuing "vexatious" litigation against Indian competitors.